EcoDrugPlus

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSOKIG00005037770
Gene Symbol: PSMC5
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSOKIG00005033250
Gene Symbol: PSMC6
1 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSOKIG00005033095
Gene Symbol: PSMD1
1 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSOKIG00005002435
Gene Symbol: PSMD11
3 Cross references
200 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSOKIG00005030783
Gene Symbol: PSMD11
1 Cross references
201 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSOKIG00005019096
Gene Symbol: PSMD12
3 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSOKIG00005047101
Gene Symbol: PSMD12
1 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSOKIG00005030286
Gene Symbol: PSMD13
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSOKIG00005036741
Gene Symbol: PSMD7
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSOKIG00005000329
Gene Symbol: PSMD7
3 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSOKIG00005032046
Gene Symbol: PSMD8
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-2

Ensembl ID : ENSOKIG00005047231
Gene Symbol: LOC109884242
2 Cross references
70 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).